135 related articles for article (PubMed ID: 34283300)
1. Acute renal disease in patients with ovarian peritoneal carcinomatosis treated with cytoreduction and HIPEC: the influence of surgery and the cytostatic agent used.
Gómez-Ruiz ÁJ; González-Gil A; Gil J; Alconchel F; Navarro-Barrios Á; Gil-Gómez E; Martínez J; Nieto A; García-Palenciano C; Cascales-Campos PA
Langenbecks Arch Surg; 2021 Nov; 406(7):2449-2456. PubMed ID: 34283300
[TBL] [Abstract][Full Text] [Related]
2. "Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances".
Arjona-Sánchez A; Cadenas-Febres A; Cabrera-Bermon J; Muñoz-Casares FC; Casado-Adam A; Sánchez-Hidalgo JM; López-Andreu M; Briceño-Delgado J; Rufián-Peña S
Eur J Surg Oncol; 2016 Jun; 42(6):869-76. PubMed ID: 26898841
[TBL] [Abstract][Full Text] [Related]
3. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
5. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
[TBL] [Abstract][Full Text] [Related]
7. The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study.
Manzanedo I; Pereira F; Serrano Á; Pérez-Viejo E; Martínez-Torres B; Carrión L; Calzas J
Clin Transl Oncol; 2019 Oct; 21(10):1357-1363. PubMed ID: 30788835
[TBL] [Abstract][Full Text] [Related]
8. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.
Ye J; Ren Y; Wei Z; Peng J; Chen C; Song W; Tan M; He Y; Yuan Y
Surg Oncol; 2018 Sep; 27(3):456-461. PubMed ID: 30217302
[TBL] [Abstract][Full Text] [Related]
10. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
[TBL] [Abstract][Full Text] [Related]
11. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
Sin EI; Chia CS; Tan GHC; Soo KC; Teo MC
Int J Hyperthermia; 2017 Sep; 33(6):690-695. PubMed ID: 28540777
[TBL] [Abstract][Full Text] [Related]
12. Eliminating the need for preoperative intravenous hyperhydration: Sodium thiosulfate as nephrotoxicity prevention in HIPEC-treated patients - A retrospective analysis.
Vachez E; Kefleyesus A; Bakrin N; Ranchon F; Rioufol C; Vassal O; Al-Hadeedi O; Kepenekian V; Glehen O
Eur J Surg Oncol; 2024 Feb; 50(2):107955. PubMed ID: 38219699
[TBL] [Abstract][Full Text] [Related]
13. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery.
Hakeam HA; Breakiet M; Azzam A; Nadeem A; Amin T
Ren Fail; 2014 Nov; 36(10):1486-91. PubMed ID: 25155314
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy.
Cheng CC; Yeh HC; Su PW; Ho CL; Chang SC
Int J Hyperthermia; 2024; 41(1):2304250. PubMed ID: 38342495
[TBL] [Abstract][Full Text] [Related]
17. HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study.
Sugarbaker PH; Stuart OA
Surg Oncol; 2020 Dec; 35():441-446. PubMed ID: 33039850
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA).
Villarejo Campos P; Sánchez García S; Amo-Salas M; García Santos E; López de la Manzanara C; Alberca A; Padilla-Valverde D; Redondo Calvo FJ; Martín J
Curr Oncol; 2024 Jan; 31(2):660-671. PubMed ID: 38392042
[TBL] [Abstract][Full Text] [Related]
19. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
20. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
Vaira M; Robella M; Mellano A; Sottile A; De Simone M
Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
